Table 6. Univariate and multivariate analyses of prognostic value of serum bilirubin.
| Factors | Training cohort | Validation cohort | ||||
|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||
| P | HR (95%CI) | P | P | HR (95%CI) | P | |
| Age (years) | 0.085 | 0.234 | ||||
| Sex (male) | 0.124 | 0.162 | ||||
| Smoking | 0.541 | 0.324 | ||||
| ECOG PS (2–3) | 0.594 | 0.160 | ||||
| Histological type | 0.220 | 0.108 | ||||
| TNM stage | <0.001 | <0.001 | ||||
| I | Reference | Reference | ||||
| II | 1.24 (0.96–3.25) | 0.057 | 1.30 (1.11–2.64) | 0.020 | ||
| III | 2.59 (1.20–4.98) | <0.001 | 2.42 (1.14–3.58) | <0.001 | ||
| pT stage | <0.001 | <0.001 | ||||
| T1–2 | Reference | Reference | ||||
| T3–4 | 2.45 (1.22–5.19) | <0.001 | 1.99 (1.12–3.20) | 0.002 | ||
| pN stage | <0.001 | <0.001 | ||||
| T0–1 | Reference | Reference | ||||
| T2–3 | 1.86 (1.08–2.80) | 0.005 | 2.00 (1.20–3.52) | <0.001 | ||
| chemotherapy | 0.042 | 1.14 (0.95–1.86) | 0.089 | 0.030 | 1.23 (0.82–1.64) | 0.124 |
| CEA (abnormal) | 0.385 | 0.110 | ||||
| TBIL (≥15 μmol/L) | 0.005 | 0.98 (0.76–1.24) | 0.582 | 0.012 | 1.01 (0.65–1.09) | 0.101 |
| DBIL (≥4.5 μmol/L) | <0.001 | 0.64 (0.52–0.91) | 0.004 | 0.004 | 0.74 (0.61–0.88) | <0.001 |
| IBIL (≥9.1 μmol/L) | 0.032 | 1.00 (0.80–1.35) | 0.532 | 0.001 | 0.94 (0.56–1.02) | 0.098 |
ECOG PS, Eastern Cooperative Oncology Group performance status; TBIL, total bilirubin; DBIL, direct bilirubin; IBIL, indirect bilirubin.